E-course: NMIBC – BCG Unresponsive management in 2025 and new developments
This e-course will focus on Bacillus Calmette-Guérin–unresponsive (BCG-U) non-muscle-invasive bladder cancer (NMIBC).
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | 1.00 |
| Duration | Approx. 60 minutes |
BCG-U NMIBC remains to be a therapeutic challenge due to its substantial risk of progression to muscle-invasive bladder cancer (MIBC), and requires further management including radical cystectomy (RC). In this context, different intravesical and systemic therapies (immunotherapies, gene therapies and drug-delivery devices) emerge as promising alternatives to delay or potentially avoid RC.
In this e-course, we will discuss a clinical case of a patient with high-grade BCG-U NMIBC, and examine the different therapeutic options including intravesical and systemic therapies. We will also analyse the efficacy data, as well as the benefit-risk balance including risk of progression and adverse events.
Speakers:
- Prof. Dr. E.N. Xylinas (FR)
- Dr. G. Marcq (FR)
- Prof. S. Shariat (AT)
- Dr. F. Soria (IT)
This recording is brought to you in collaboration with the EAU Section of Oncological Urology.